Pathstone Holdings
ABCL icon

Pathstone Holdings’s AbCellera Biologics ABCL Stock Holding History

Pathstone Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,811
Closed -$43.9K – 2329
2025
Q2 		$43.9K Sell
12,811
-8,052
-39% -$20K ﹤0.01% 2150
2025
Q1 		$46.5K Sell
20,863
-500
-2% -$1.43K ﹤0.01% 2180
2024
Q4 		$62.6K Sell
21,363
-10,140
-32% -$28.2K ﹤0.01% 2255
2024
Q3 		$81.9K Buy
31,503
+14,693
+87% +$40.7K ﹤0.01% 2256
2024
Q2 		$49.8K Sell
16,810
-228
-1% -$863 ﹤0.01% 2266
2024
Q1 		$77.2K Buy
17,038
+324
+2% +$1.65K ﹤0.01% 2236
2023
Q4 		$95.4K Buy
+16,714
New +$77.5K ﹤0.01% 2151

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Pathstone Holdings's ABCL Position: Q3 2025 in Review

Pathstone Holdings sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 12,811 shares — an estimated $43.9K sold.

Pathstone Holdings first reported a position in ABCL in Q4 2023 and held it in 7 quarters. The position peaked at $95.4K in Q4 2023. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • Pathstone Holdings reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • Pathstone Holdings sold 12,811 AbCellera Biologics shares in Q3 2025, an estimated $43.9K.
  • Pathstone Holdings first reported a position in AbCellera Biologics in Q4 2023 and held it in 7 quarters.
  • Pathstone Holdings's AbCellera Biologics position peaked at $95.4K in Q4 2023.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Pathstone Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.